Study identifier:NIS-RCN-XXX-2012/1
ClinicalTrials.gov identifier:NCT01753427
EudraCT identifier:N/A
CTIS identifier:N/A
Perception of symptom variability in Chinese COPD patients
Chronic Obstructive Pulmonary Disease
N/A
No
-
All
1058
Observational
40 Years +
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: -
Verified 01 Jun 2016 by AstraZeneca
AstraZeneca
-
The objective of the study is to assess patient's perception with stable state COPD on symptom variability and to describe how symptom variability impacts daily quality of life in Chinese COPD patient with moderate, severe or very severe airflow limitation from tier 3 hospitals in China where most of COPD patients are diagnosed and treated.
Location
Location
Beijing, Beijing, China
Location
Guangzhou, Guangdong, China
Location
Shanghai, Shanghai, China
Location
Wuhan, Hubei, China
Location
Chengdu, Sichuan, China
Location
Tianjin, Tianjin, China
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.